T Roice Fulton1,2, Varun K Phadke3, Walter A Orenstein4,5, Alan R Hinman6, Wayne D Johnson2, Saad B Omer1,2,4,5. 1. Department of Global Health. 2. Department of Epidemiology, Rollins School of Public Health, Emory University. 3. Division of Infectious Diseases, Emory University School of Medicine. 4. Emory Vaccine Center. 5. Department of Pediatrics, Emory University School of Medicine, Atlanta. 6. The Task Force for Global Health, Decatur, Georgia.
Abstract
BACKGROUND: Acellular pertussis (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-term (<3 years after completion of the primary series) efficacy. However, vaccine effect varies between individual pertussis vaccine formulations, and many originally studied formulations are now unavailable. An updated analysis of the short-term protective effect of pertussis vaccines limited to formulations currently on the market in developed countries is needed. METHODS: We conducted a systematic review and meta-analysis of published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 years after completion (>3 doses) of a primary series of a currently available aP or wP vaccine formulation. The primary outcome was based on the World Health Organization (WHO) clinical case definitions for pertussis. Study quality was assessed using the approach developed by the Child Health Epidemiology Research Group. We determined overall effect sizes using random-effects meta-analyses, stratified by vaccine (aP or wP) and study (efficacy or effectiveness) type. RESULTS: Meta-analysis of 2 aP vaccine efficacy studies (assessing the 3-component GlaxoSmithKline and 5-component Sanofi-Pasteur formulations) yielded an overall aP vaccine efficacy of 84% (95% confidence interval [CI], 81%-87%). Meta-analysis of 3 wP vaccine effectiveness studies (assessing the Behringwerke, Pasteur/Mérieux, and SmithKline Beecham formulations) yielded an overall wP vaccine effectiveness of 94% (95% CI, 88%-97%) (bothI(2)= 0%). CONCLUSIONS: Although all contemporary aP and wP formulations protect against pertussis disease, in this meta-analysis the point estimate for short-term protective effect against WHO-defined pertussis in young children was lower for currently available aP vaccines than wP vaccines.
BACKGROUND: Acellular pertussis (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-term (<3 years after completion of the primary series) efficacy. However, vaccine effect varies between individual pertussis vaccine formulations, and many originally studied formulations are now unavailable. An updated analysis of the short-term protective effect of pertussis vaccines limited to formulations currently on the market in developed countries is needed. METHODS: We conducted a systematic review and meta-analysis of published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 years after completion (>3 doses) of a primary series of a currently available aP or wP vaccine formulation. The primary outcome was based on the World Health Organization (WHO) clinical case definitions for pertussis. Study quality was assessed using the approach developed by the Child Health Epidemiology Research Group. We determined overall effect sizes using random-effects meta-analyses, stratified by vaccine (aP or wP) and study (efficacy or effectiveness) type. RESULTS: Meta-analysis of 2 aP vaccine efficacy studies (assessing the 3-component GlaxoSmithKline and 5-component Sanofi-Pasteur formulations) yielded an overall aP vaccine efficacy of 84% (95% confidence interval [CI], 81%-87%). Meta-analysis of 3 wP vaccine effectiveness studies (assessing the Behringwerke, Pasteur/Mérieux, and SmithKline Beecham formulations) yielded an overall wP vaccine effectiveness of 94% (95% CI, 88%-97%) (bothI(2)= 0%). CONCLUSIONS: Although all contemporary aP and wP formulations protect against pertussis disease, in this meta-analysis the point estimate for short-term protective effect against WHO-defined pertussis in young children was lower for currently available aP vaccines than wP vaccines.
Authors: Pamela Rendi-Wagner; Michael Kundi; Andrea Mikolasek; Andreas Vécsei; Martin Frühwirth; Herwig Kollaritsch Journal: Vaccine Date: 2006-05-23 Impact factor: 3.641
Authors: J G Liese; C K Meschievitz; E Harzer; J Froeschle; P Hosbach; J E Hoppe; F Porter; S Stojanov; K Niinivaara; A M Walker; B H Belohradsky Journal: Pediatr Infect Dis J Date: 1997-11 Impact factor: 2.129
Authors: Kristine M Bisgard; Philip Rhodes; Beverly L Connelly; Daoling Bi; Christine Hahn; Sarah Patrick; Mary P Glodé; Kristen R Ehresmann Journal: Pediatrics Date: 2005-08 Impact factor: 7.124
Authors: F Simondon; M P Preziosi; A Yam; C T Kane; L Chabirand; I Iteman; G Sanden; S Mboup; A Hoffenbach; K Knudsen; N Guiso; S Wassilak; M Cadoz Journal: Vaccine Date: 1997-10 Impact factor: 3.641
Authors: D Greco; S Salmaso; P Mastrantonio; M Giuliano; A E Tozzi; A Anemona; M L Ciofi degli Atti; A Giammanco; P Panei; W C Blackwelder; D L Klein; S G Wassilak Journal: N Engl J Med Date: 1996-02-08 Impact factor: 91.245
Authors: Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette Journal: J Clin Invest Date: 2018-08-06 Impact factor: 14.808
Authors: Natasha S Crowcroft; Kevin L Schwartz; Rachel D Savage; Cynthia Chen; Caitlin Johnson; Ye Li; Alex Marchand-Austin; Shelly Bolotin; Shelley L Deeks; Frances B Jamieson; Steven J Drews; Margaret L Russell; Lawrence W Svenson; Kimberley Simmonds; Christiaan H Righolt; Christopher Bell; Salaheddin M Mahmud; Jeffrey C Kwong Journal: Clin Infect Dis Date: 2021-07-01 Impact factor: 9.079
Authors: Breanna Barger-Kamate; Maria Deloria Knoll; E Wangeci Kagucia; Christine Prosperi; Henry C Baggett; W Abdullah Brooks; Daniel R Feikin; Laura L Hammitt; Stephen R C Howie; Orin S Levine; Shabir A Madhi; J Anthony G Scott; Donald M Thea; Tussanee Amornintapichet; Trevor P Anderson; Juliet O Awori; Vicky L Baillie; James Chipeta; Andrea N DeLuca; Amanda J Driscoll; Doli Goswami; Melissa M Higdon; Lokman Hossain; Ruth A Karron; Susan Maloney; David P Moore; Susan C Morpeth; Lawrence Mwananyanda; Ogochukwu Ofordile; Emmanuel Olutunde; Daniel E Park; Samba O Sow; Milagritos D Tapia; David R Murdoch; Katherine L O'Brien; Karen L Kotloff Journal: Clin Infect Dis Date: 2016-12-01 Impact factor: 9.079
Authors: Ayman Chit; Hossein Zivaripiran; Thomas Shin; Jason K H Lee; Antigona Tomovici; Denis Macina; David R Johnson; Michael D Decker; Jianhong Wu Journal: PLoS One Date: 2018-06-18 Impact factor: 3.240
Authors: Marie J Estcourt; Julie A Marsh; Dianne E Campbell; Michael S Gold; Katrina J Allen; Peter Richmond; Claire S Waddington; Thomas L Snelling Journal: BMJ Open Date: 2018-01-31 Impact factor: 2.692